Fundies.
English

Armata Pharmaceuticals, Inc.

EDGAR
APHB Quarterly report (10-Q) · filed 2026-08-12

139 filing records in this dataset, filed from 1996-08-12 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
24 million Unit_Standard_USD_1VWH2ZD9LEGuX4g5bpfVSA Source
Exact value

24000000 Unit_Standard_USD_1VWH2ZD9LEGuX4g5bpfVSA

Long-term debt including current maturities
Not available
Shares outstanding
37.1 million Unit_Standard_shares_2E9Ch_cdzk27dxa_2LgupQ Source
Exact value

37145720 Unit_Standard_shares_2E9Ch_cdzk27dxa_2LgupQ

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 2 of 11 periods available· newest 2025-12-31
  • Net income: 2 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2025-12-31
  • Total assets: Multiple units; comparison withheld· newest 2025-12-31
  • Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Current assets: Multiple units; comparison withheld· newest 2025-12-31
  • Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 154.88 million

    Prior period

    −Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 18.92 million

    –

    Current period

    −Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 173.8 million

    –

    Exact inputs and evidence

    -173799000 − -18916000 = -154883000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

    -18916000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -173799000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 11.79 million

    Prior period

    −Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 37.55 million

    –

    Current period

    −Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 25.76 million

    –

    Exact inputs and evidence

    -25763000 − -37551000 = 11788000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

    -37551000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -25763000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    -71.2%

    Prior period

    Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 1.88 million

    –

    Current period

    Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 542,000

    –

    Exact inputs and evidence

    542000 − 1879000 = -1337000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

    1879000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    542000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2024 2024-01-01 – 2024-12-31
−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 18.92 million
Exact value

Exact value: -18916000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2024-01-01 – 2024-12-31: -18916000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 37.55 million
Exact value

Exact value: -37551000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2024-01-01 – 2024-12-31: -37551000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 1.88 million
Exact value

Exact value: 1879000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2024-01-01 – 2024-12-31: 1879000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 39.43 million
Calculation and evidence

-37551000 − 1879000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

Exact free cash flow: -39430000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 173.8 million
Exact value

Exact value: -173799000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2025-01-01 – 2025-12-31: -173799000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 25.76 million
Exact value

Exact value: -25763000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2025-01-01 – 2025-12-31: -25763000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 542,000
Exact value

Exact value: 542000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

2025-01-01 – 2025-12-31: 542000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw 26.31 million
Calculation and evidence

-25763000 − 542000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

Exact free cash flow: -26305000 Unit_Standard_USD_bWuVPCzQMUiIpJ53FlwIkw

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

139 filings · 4,349 latest values · 4,349 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0000921114, 921114, APHB, ARMP, edgar:921114

Also known as ARMATA PHARMACEUTICALS, INC., AmpliPhi Biosciences Corp, Armata Pharmaceuticals, Inc., TARGETED GENETICS CORP /WA/